Vanguard CPV suspension injectable pour chiens
Vanguard CPV suspension injectable pour chiens
Authorised
- Canine parvovirus, strain NL-35-D, Live
Product identification
Medicine name:
Vanguard CPV suspension injectable pour chiens
Vanguard CPV Injektionslösung
Active substance:
- Canine parvovirus, strain NL-35-D, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine parvovirus, strain NL-35-D, Live10000000.00/cell culture infective dose 501.00millilitre(s)
Pharmaceutical form:
-
Suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AD01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Luxembourg
Package description:
- Vanguard CPV 1 dose Vial Suspension for injection
- Vanguard CPV 10 1 dose Vial Suspension for injection
- Vanguard CPV 25 1 dose Vial Suspension for injection
- Vanguard CPV 100 1 dose Vial Suspension for injection
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium
Responsible authority:
- Ministere De La Sante Division De La Pharmacie Et Des Medicaments
Authorisation number:
- V 087/93/11/0349
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 16/01/2024
How useful was this page?:
